Pure Global AI
NCT06156280Recruiting

A Clinical Study of TQH2929 in Healthy Adult Subjects

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
TQH2929 injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Funder
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Nov 21, 2023
End date
Apr 01, 2025
Enrollment
78 participants
Primary outcome

Adverse events (AE) rate,Serious adverse events (SAE) rate,Treatment-related adverse events (TRAE) rate,Clinical laboratory abnormalities

Summary

This project is divided into a single dose escalation and a multiple dose escalation phase Ia
 clinical study. This is a single-center, randomized, double-blind, placebo-controlled study
 to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929
 injection in healthy adults.

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06156280
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06156280 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 78 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.